Evaxion Biotech 株価情報 (NASDAQ: EVAX)

最新ニュース Evaxion Biotech (NASDAQ:EVAX) 株価情報

Evaxion Biotech

Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.

Evaxion Biotech A/S - American Depositary Share

Evaxion Biotech AS

Piper Sandler analyst Michael Lavery upgraded the shares of Tyson Foods Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSN#NYSE">TSN</a>) from Underweight to Neutral and maintained the <a target="_blank" href="https://www.benzinga.com/quote/TSN/analyst-ratings" rel="noreferrer noopener">price forecast of $58.</a>
TSN reported a 9.1% Chicken EBIT margin in the first quarter, surpassing the analyst&#8217;s 6.5% forecast, marking its <a target="_blank" href="https://www.benzinga.com/news/earnings/25/02/43432806/tyson-foods-posts-q1-earnings-protein-conscious-customers-drive-demand-ceo-calls-it-best-quarter-in-2-years" rel="noreferrer noopener">best quarter since the second quarter of FY2018.</a>
The company achieved a Chicken order fill rate of over 98%, thanks to improvements in scheduling and execution that better aligned production with demand.
Tyson Foods also reduced waste in its plants. Both retail and food service segments are expanding, with strong performance in its value-added portfolio. Additionally, it reintroduced fully cooked products in retail during the first quarter.
The analyst forecasts a 7.4% Chicken EBIT margin for F25, though feed cost benefits are expected to diminish in later quarters.
Cattle supply remains limited, and price spreads are narrow, but prices have stayed high due to stronger-than-expected consumer demand, said the analyst.
The analyst anticipates that heifer retention may increase, which would be beneficial for herd rebuilding in the long run, but could reduce near-term supply and potentially pressure margins further.
On February 1, 2025, President Trump announced that the U.S. would impose a <a target="_blank" href="https://www.benzinga.com/markets/25/02/43423288/trumps-tariffs-are-here-heres-what-will-get-more-expensive-from-canada-china-and-mexico" rel="noreferrer noopener">25% tariff on all imports</a> from Canada and Mexico, effective February 4, 2025.
However, U.S. and Mexico have agreed to <a target="_blank" href="https://www.benzinga.com/government/regulations/25/02/43440692/us-mexico-agrees-on-one-month-tariffs-pause-stocks-rebound-peso-rallies" rel="noreferrer noopener">postpone the tariffs</a> for a month to focus on combating the fentanyl trade.
Related Read: <a target="_blank" href="https://in.benzinga.com/25/02/43450261/trump-trudeau-strike-border-security-deal-tariffs-on-canada-paused-for-at-least-30-days" rel="noreferrer noopener">Trump, Trudeau Strike Border Security Deal, Tariffs On Canada Paused For &#8216;At Least 30 Days&#8217;</a>
Tyson Foods exports a limited amount of chicken products to Canada and sends around 2.5% of its pork sales, along with some chicken leg quarters, to Mexico. Additionally, it imports feeder cows and hogs from Canada.
Tyson Foods is prepared to adjust to any tariffs, with contingency plans in place to pivot to other markets quickly, opined the analyst.
While the analyst expects solid EBIT for the second and third quarters, the outlook for future quarters remains uncertain. The analyst has raised the FY25 EPS estimate from $3.45 to $3.93 but kept the FY26 EPS at $4.55 and the target price at $58.
Price Action: TSN shares are trading lower by 1.54% at $56.85 at the last check Tuesday.
Photo via Shutterstock.

Analyst Color

Equities

News

Upgrades

Price Target

Analyst Ratings

Trading Ideas

General

Tyson Foods Stock Trading Around Fair Value, Analyst Upgrades Stock To Neutral

Investors with a lot of money to spend have taken a bullish stance on Nike (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with NKE, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 20 uncommon options trades for Nike.
This isn't normal.
The overall sentiment of these big-money traders is split between 55% bullish and 45%, bearish.
Out of all of the special options we uncovered, 6 are puts, for a total amount of $324,640, and 14 are calls, for a total amount of $586,055.
<h3>Projected Price Targets</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $66.0 to $85.0 for Nike over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Nike's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Nike's whale trades within a strike price range from $66.0 to $85.0 in the last 30 days. 
<h3>Nike Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738694733_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NKE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/07/25</td>
<td>$3.25</td>
<td>$3.2</td>
<td>$3.25</td>
<td>$75.00</td>
<td>$145.6K</td>
<td>3.8K</td>
<td align="right">109</td>
</tr>
<tr>
<td>NKE</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$11.7</td>
<td>$11.55</td>
<td>$11.55</td>
<td>$82.50</td>
<td>$125.8K</td>
<td>2.6K</td>
<td align="right">0</td>
</tr>
<tr>
<td>NKE</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$5.6</td>
<td>$5.55</td>
<td>$5.6</td>
<td>$75.00</td>
<td>$57.6K</td>
<td>1.3K</td>
<td align="right">109</td>
</tr>
<tr>
<td>NKE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$14.25</td>
<td>$14.0</td>
<td>$14.25</td>
<td>$70.00</td>
<td>$57.0K</td>
<td>567</td>
<td align="right">41</td>
</tr>
<tr>
<td>NKE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$11.55</td>
<td>$11.55</td>
<td>$11.55</td>
<td>$70.00</td>
<td>$46.2K</td>
<td>431</td>
<td align="right">47</td>
</tr>
</tbody>
</table>

<h3>About Nike</h3>
Nike is the largest athletic footwear and apparel brand in the world. Key categories include basketball, running, and football (soccer). Footwear generates about two thirds of its sales. Its brands include Nike, Jordan (premium athletic footwear and clothing), and Converse (casual footwear). Nike sells products worldwide through company-owned stores, franchised stores, and third-party retailers. The firm also operates e-commerce platforms in more than 40 countries. Nearly all its production is outsourced to contract manufacturers in more than 30 countries. Nike was founded in 1964 and is based in Beaverton, Oregon.
In light of the recent options history for Nike, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Where Is Nike Standing Right Now?</h3>
<ul>
<li>With a volume of 5,606,686, the price of NKE is up 0.2% at $76.74. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 44 days.</li>
</ul>
<h3>What The Experts Say On Nike</h3>
A total of 2 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $92.5.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from BMO Capital has decided to maintain their Outperform rating on Nike, which currently sits at a price target of $95. 
&#x2A; An analyst from Piper Sandler upgraded its action to Overweight with a price target of $90. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Nike, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Markets

Nike's Options Frenzy: What You Need to Know

High-rolling investors have positioned themselves bullish on Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), and it's important for retail traders to take note. 
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in PFE often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 33 options trades for Pfizer. This is not a typical pattern.
The sentiment among these major traders is split, with 66% bullish and 33% bearish. Among all the options we identified, there was one put, amounting to $46,800, and 32 calls, totaling $4,965,419.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $20.0 and $30.0 for Pfizer, spanning the last three months.
<h3>Analyzing Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Pfizer's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Pfizer's significant trades, within a strike price range of $20.0 to $30.0, over the past month.
<h3>Pfizer Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738694728_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$1.39</td>
<td>$1.34</td>
<td>$1.34</td>
<td>$26.00</td>
<td>$1.9M</td>
<td>933</td>
<td>15.3K</td>
</tr>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$0.85</td>
<td>$0.82</td>
<td>$0.82</td>
<td>$26.00</td>
<td>$1.2M</td>
<td>21.0K</td>
<td>16.3K</td>
</tr>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/14/25</td>
<td>$1.4</td>
<td>$1.39</td>
<td>$1.4</td>
<td>$25.00</td>
<td>$243.8K</td>
<td>139</td>
<td>8.1K</td>
</tr>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/14/25</td>
<td>$1.43</td>
<td>$1.25</td>
<td>$1.43</td>
<td>$25.00</td>
<td>$150.2K</td>
<td>139</td>
<td>9.9K</td>
</tr>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/14/25</td>
<td>$1.4</td>
<td>$1.4</td>
<td>$1.4</td>
<td>$25.00</td>
<td>$132.4K</td>
<td>139</td>
<td>6.0K</td>
</tr>
</tbody>
</table>

<h3>About Pfizer</h3>
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
After a thorough review of the options trading surrounding Pfizer, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Where Is Pfizer Standing Right Now?</h3>
<ul>
<li>With a trading volume of 45,035,165, the price of PFE is down by -1.85%, reaching $25.71.</li>
<li>Current RSI values indicate that the stock is may be approaching oversold.</li>
<li>Next earnings report is scheduled for 0 days from now.</li>
</ul>
<h3>Expert Opinions on Pfizer</h3>
2 market experts have recently issued ratings for this stock, with a consensus target price of $29.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from UBS continues to hold a Neutral rating for Pfizer, targeting a price of $29. 
&#x2A; Consistent in their evaluation, an analyst from Citigroup keeps a Neutral rating on Pfizer with a target price of $29. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Pfizer with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Unpacking the Latest Options Trading Trends in Pfizer

Deep-pocketed investors have adopted a bearish approach towards Celestica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLS#NYSE">CLS</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in CLS usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 20 extraordinary options activities for Celestica. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 20% leaning bullish and 55% bearish. Among these notable options, 3 are puts, totaling $120,280, and 17 are calls, amounting to $746,958.
<h3>Predicted Price Range</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $85.0 and $175.0 for Celestica, spanning the last three months.
<h3>Volume &amp; Open Interest Development</h3>
In today's trading context, the average open interest for options of Celestica stands at 601.94, with a total volume reaching 980.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Celestica, situated within the strike price corridor from $85.0 to $175.0, throughout the last 30 days.
<h3>Celestica Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738694722_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CLS</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/21/25</td>
<td>$24.1</td>
<td>$21.7</td>
<td>$23.0</td>
<td>$105.00</td>
<td>$158.7K</td>
<td>2.7K</td>
<td align="right">102</td>
</tr>
<tr>
<td>CLS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/28/25</td>
<td>$45.5</td>
<td>$44.2</td>
<td>$45.01</td>
<td>$85.00</td>
<td>$54.0K</td>
<td>161</td>
<td align="right">58</td>
</tr>
<tr>
<td>CLS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$25.7</td>
<td>$25.5</td>
<td>$25.7</td>
<td>$140.00</td>
<td>$51.4K</td>
<td>120</td>
<td align="right">22</td>
</tr>
<tr>
<td>CLS</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/28/25</td>
<td>$40.9</td>
<td>$40.0</td>
<td>$40.39</td>
<td>$90.00</td>
<td>$48.4K</td>
<td>156</td>
<td align="right">56</td>
</tr>
<tr>
<td>CLS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$11.8</td>
<td>$11.3</td>
<td>$11.35</td>
<td>$130.00</td>
<td>$45.4K</td>
<td>1.2K</td>
<td align="right">38</td>
</tr>
</tbody>
</table>

<h3>About Celestica</h3>
Celestica Inc offers supply chain solutions. The company has two operating and reportable segments: Advanced Technology Solutions (ATS) and Connectivity &amp; Cloud Solutions (CCS). The ATS segment consists of the ATS end market and is comprised of the Aerospace and Defense, Industrial, health tech, and Capital Equipment businesses. Its Capital Equipment business is comprised of the semiconductor, display, and robotics equipment businesses, and the CCS segment consists of Communications and Enterprise end markets, Enterprise end market is comprised of its servers and storage businesses. The company generates a majority of its revenue from the Connectivity &amp; Cloud Solutions segment.
After a thorough review of the options trading surrounding Celestica, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Celestica's Current Market Status</h3>
<ul>
<li>With a volume of 3,283,755, the price of CLS is up 8.55% at $131.21. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 78 days.</li>
</ul>
<h3>What Analysts Are Saying About Celestica</h3>
In the last month, 4 experts released ratings on this stock with an average target price of $125.25.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from TD Securities persists with their Buy rating on Celestica, maintaining a target price of $107. 
&#x2A; An analyst from RBC Capital persists with their Outperform rating on Celestica, maintaining a target price of $140. 
&#x2A; Consistent in their evaluation, an analyst from RBC Capital keeps a Outperform rating on Celestica with a target price of $115. 
&#x2A; An analyst from Barclays persists with their Overweight rating on Celestica, maintaining a target price of $139. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Celestica, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Celestica's Options Frenzy: What You Need to Know

Spirit Aero Has Increased Fuselage Production From A Rate Of 21 A Month To 31 A Month, According To A Source Familiar With The Matter; Spirit Aero Spokesperson Joe Buccino Said The Company "Remains Committed To Meeting Our Customer's Production Targets."

BofA Securities analyst Wamsi Mohan reiterated a Buy rating on Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) with a <a target="_blank" href="https://www.benzinga.com/quote/AAPL/analyst-ratings" rel="noreferrer noopener">price target of $265</a>.
As per SensorTower data, App Store revenues in the second quarter of fiscal 2025 (after 36 days) increased to $3.4 billion (+17%, according to data on developer revenue from SensorTower), with total downloads (iPhone + iPad) +6.5% (3.7 billion) during the same period. For January, App store revenue increased by +18% globally and +17% in China.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/25/02/43468780/fox-q2-earnings-revenue-and-eps-beat-fall-sports-schedule-and-election-cycle-drove-performance-plans-new-streaming-service" rel="noreferrer noopener">Fox Q2 Earnings: Revenue And EPS Beat, Fall Sports Schedule and Election Cycle Drove Performance, Plans New Streaming Service</a>
In the second quarter of fiscal 2025 (after 36 days), Mohan noted an increase of app store dollars per download by +9.8%.
The rerating reflects stable cash flows, earnings resiliency and potential beneficiary of AI use on edge devices.
The Productivity category of Apps has been the fastest growing segment in the second quarter, with revenues rising +48% after 36 days. The growth in Productivity app revenue to Apple in the quarter has been driven by ChatGPT, which has seen daily active users grow from ~5.5 million in the first 36 days of the second quarter of fiscal 2024 to more than 15 million in the first 36 days of second-quarter of fiscal 2025.
So far, in the second quarter of fiscal 2025, App Store gaming revenue increased +12% to $1.7 billion, accounting for only 51% of total App Store revenue versus 53% a year ago. So far in the quarter, the second largest segment has been Entertainment (14%), Photo and video (7%), Social Networking (4%), Productivity (3%), and Other (21%).
Mohan noted strong diversification in app store revenue by category away from the Gaming segment as more developers from other categories monetize apps.
Apple noted that certain EU apps that do not conform to Apple&#8217;s standard of scrutiny over content are available to download. This ability to sideload apps is a result of the EU DMA restrictions, which might compromise user safety.
Mohan modeled services revenue growth of +12% for total services revenue in the second quarter of fiscal 2025 and +13% in fiscal 2025, which could be conservative if App Store strength persists.
Price Action: AAPL stock is up 1.64% at $231.75 at last check Tuesday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/02/43468852/ferrari-q4-earnings-top-estimates-ceo-highlights-robust-growth-in-2025" target="_blank" rel="noreferrer noopener">Ferrari Q4 Earnings Top Estimates, CEO Highlights &#8216;Robust Growth&#8217; In 2025</a></li>
</ul>
Image via Shutterstock

Reiteration

Tech

AAPL

Apple's App Store Booms As ChatGPT, Productivity Apps Drive Revenue Growth, Analyst Says

Boeing's Mounir Says Co. Minimizing Supplier Work Transfers To Improve Quality; Supply Chain Exec Says Work Transfers Among Suppliers Are Leading Cause Of Quality Defects; Exec Says Spirit AeroSystems Quality Has Significantly Improved, Has Substantial Inventory Of 737 Fuselages Ready To Ship To Boeing Plant

Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) will release its fourth-quarter financial results after the <a href="https://www.benzinga.com/quote/goog/earnings">closing bell on Tuesday, Feb. 4.</a>
Analysts expect the California-based company to report quarterly earnings at $2.13 per share, up from $1.64 per share in the year-ago period. Alphabet projects quarterly revenue of $96.65 billion, compared to $ 86.31 billion a year earlier, according to data from Benzinga Pro.
Recent strength in advertising for Meta Platforms could foreshadow strong advertising strength for Alphabet, Bank of America analyst Justin Post recently said.
Alphabet shares fell 1.4% to close at $202.64 on Monday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/GOOG/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>Oppenheimer analyst Jason Helfstein maintained an Outperform rating and raised the price target from $215 to $225 on Jan. 30, 2025. This analyst has an accuracy rate of 80%.</li>
<li>Scotiabank analyst Nat Schindler maintained a Sector Outperform rating and raised the price target from $212 to $240 on Jan. 24, 2025. This analyst has an accuracy rate of 65%.</li>
<li>Jefferies analyst Brent Thill maintained a Buy rating and raised the price target from $220 to $235 on Oct. 30, 2024. This analyst has an accuracy rate of 77%.</li>
<li>Pivotal Research analyst Jeffrey Wlodarczak maintained a Buy rating and boosted the price target from $215 to $225 on Oct. 30, 2024. This analyst has an accuracy rate of 67%.</li>
<li>UBS analyst Lloyd Walmsley maintained a Neutral rating and increased the price target from $187 to $192 on Oct. 30, 2024. This analyst has an accuracy rate of 85%.</li>
</ul>
Considering buying GOOG stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="580" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04043744/image-16-1024x580.png" alt="" class="wp-image-764391" style="width:644px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04043744/image-16-1024x580.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04043744/image-16-300x170.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04043744/image-16-768x435.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04043744/image-16.png 1122w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43432950/jim-cramer-appfolio-is-a-cheap-stock-dont-sell-this-tech-stock">Jim Cramer Says AppFolio Is A &#8216;Good One,&#8217; But Summit Therapeutics? &#8216;Can&#8217;t Go There&#8217;</a></li>
</ul>

Earnings

GOOG

GOOGL

Alphabet Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Fabrinet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FN#NYSE">FN</a>) reported upbeat second-quarter <a href="https://www.benzinga.com/quote/FN/earnings">results on Monday</a>.
Revenue was $833.6 million, beating the consensus of $814.3 million. Adjusted EPS of $2.61 exceeded the consensus of $2.50.
"Our telecom performance was very strong and benefited from both increasing demand for datacenter interconnect products as well as early progress from recent systems wins," Seamus Grady, Chief Executive Officer of Fabrinet, said. "While datacom demand has slightly moderated near-term we continue to anticipate more rapid growth as next-generation products ramp production. With several positive trends, we are very optimistic as we look to the third quarter and beyond."
Fabrinet expects third-quarter FY25 revenue of $850 million – $870 million, surpassing street view of $825.72 million. The company also projects adjusted EPS of $2.55 – $2.63 vs. street view of $2.55.
Fabrinet shares fell 9.6% to trade at $203.79 on Tuesday.
These analysts made changes to their price targets on Fabrinet following earnings announcement.
<ul>
<li>JP Morgan analyst Samik Chatterjee maintained Fabrinet with a Neutral and lowered the price target from $275 to $265.</li>
<li>Barclays analyst George Wang maintained Fabrinet with an Equal-Weight and lowered the price target from $292 to $245.</li>
<li>Rosenblatt analyst Mike Genovese maintained the stock with a Buy and raised the price target from $280 to $285.</li>
<li>Needham analyst Ryan Koontz, meanwhile, reiterated Fabrinet with a Buy and maintained a $280 price target.</li>
</ul>
Considering buying FN stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="483" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04133927/image-29-1024x483.png" alt="" class="wp-image-765483" style="width:555px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04133927/image-29-1024x483.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04133927/image-29-300x142.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04133927/image-29-768x362.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04133927/image-29.png 1125w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43463896/mcdonalds-to-290-here-are-10-top-analyst-forecasts-for-tuesday">McDonald&#8217;s To $290? Here Are 10 Top Analyst Forecasts For Tuesday</a></li>
</ul>

These Analysts Revise Their Forecasts On Fabrinet After Q2 Results

TD Cowen analyst Jason Seidl maintains Saia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIA#NASDAQ">SAIA</a>) with a Hold and raises the price target from $456 to $478.

SAIA

TD Cowen Maintains Hold on Saia, Raises Price Target to $478

Market volatility has intensified investors&#8217; focus on risk-adjusted strategies, with ETFs emerging as a key way to <a href="https://www.benzinga.com/etfs">gain exposure to high-growth stocks</a> without the &#8220;single-stock risk&#8221; string attached. 
Amid the back-to-back market developments, Palantir Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) is making waves with <a href="https://www.benzinga.com/news/earnings/25/02/43449486/palantir-q4-earnings-revenue-beat-eps-beat-us-revenue-up-52-customer-count-up-43-strong-guidance-this-is-a-new-phase-unlike-anything-that-has-come-before">strong Q4 results</a> where it crushed analyst expectations.
For investors seeking exposure to Palantir without direct stock ownership, these are four ETFs to keep an eye on:
Also Read: <a href="https://www.benzinga.com/analyst-ratings/price-target/25/02/43463909/palantir-stock-is-surging-tuesday-whats-going-on">Palantir Stock Is Surging Tuesday: What&#8217;s Going On?</a>
<ul>
<li>REX AI Equity Premium Income ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIPI#NASDAQ">AIPI</a>): In this ETF, Palantir holds the biggest piece of the pie, with 10.77% claim on the total assets. Expense ratio is 0.65%. The ETF inched up 0.4% on Feb. 4, 12.27 p.m. ET.</li>
</ul>
<ul>
<li>ARK Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>): Palantir consistently ranks among ARKK's top 10 holdings, reflecting Cathie Wood's strong conviction in its AI and data-driven capabilities. As of today, Palantir accounts for approximately 5.43% of ARKK's portfolio. The expense ratio is 0.75%. The ETF is currently trading relatively flat.</li>
</ul>
<ul>
<li>Global X Funds Global X Defense Tech ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHLD#NYSE">SHLD</a>): The ETF, with an expense ratio of 0.5%, reserves about 10% of its assets for Palantir. The ETF has returned 35% in the past year. The ETF rose 2.27% as of writing on Feb. 4.</li>
</ul>
<ul>
<li>First Trust US Equity Opportunities ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FPX#NYSE">FPX</a>): Though this fund tracks newly public companies, Palantir has remained a top component despite trading on the market since 2020. Palantir, with its 1000+% growth since its IPO, is a success story on its own, and this ETF capitalizes on that. FPX has around 7.05% allocation to the company stock, appealing to investors targeting high-growth IPOs. The expense ratio is 0.59%. The ETF climbed 1.05% as of writing on Feb. 4.</li>
</ul>
These ETFs allow investors to benefit from Palantir's growth graph while spreading risk across multiple high-tech stocks.
<h3 class="wp-block-heading">Why Palantir Is A Stock To Watch</h3>
Palantir soared after issuing a 2025 revenue forecast of $3.75 billion, surpassing analysts' expectations of $3.54 billion. CEO Alex Karp attributed the bullish outlook to &#8220;untamed organic growth&#8221; in AI demand. The company also projected $1.56 billion in adjusted operating income, beating estimates of $1.37 billion.
In Q4 2024, revenue jumped 36% to $827.5 million, exceeding forecasts of $775.9 million, while profit (excluding certain items) hit 14 cents per share, topping estimates of 11 cents.
Fueled by AI momentum, Palantir's stock surged 340% in 2024. After markets opened Tuesday, shares spiked 27% to a record $106.76, marking their biggest intraday gain in a year, according to Bloomberg.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/etfs/25/02/43468406/treasury-etfs-in-focus-as-trumps-tariffs-feds-rate-decision-shake-bond-markets">Treasury ETFs In Focus As Trump&#8217;s Tariffs, Fed&#8217;s Rate Decision Shake Bond Markets</a></li>
</ul>
Photo: Shutterstock

Broad U.S. Equity ETFs

Specialty ETFs

ETFs

AIPI

ARKK

PLTR

SHLD

Palantir Focused ETFs Spark Investor Interest: Here's Why

TD Cowen analyst John Kernan maintains Ralph Lauren (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RL#NYSE">RL</a>) with a Buy and raises the price target from $258 to $268.

TD Cowen Maintains Buy on Ralph Lauren, Raises Price Target to $268

Editor&#8217;s Note: This article has been updated to correct inaccuracies in company location and financial comparisons.
Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) will release its fourth-quarter financial results after the <a href="https://www.benzinga.com/quote/GOOG/earnings">closing bell on Tuesday, Feb. 4.</a>
Analysts expect the California-based company to report quarterly earnings at $2.13 per share, up from $1.64 per share in the year-ago period. Alphabet projects quarterly revenue of $96.65 billion, compared to $86.31 billion a year earlier, according to data from Benzinga Pro.
The company has beaten analyst estimates for revenue in seven straight quarters and topped analyst expectations for earnings per share in seven straight quarters.
With the recent buzz around Alphabet, some investors may be eyeing potential gains from the company's dividends too. At the moment, Alphabet offers an annual dividend yield of 0.39%, which is a quarterly dividend amount of 20 cents per share (80 cents a year).
To figure out how to earn $500 monthly from Alphabet, we start with the yearly target of $6,000 ($500 x 12 months).
Next, we take this amount and divide it by Alphabet's $0.80 dividend: $6,000 / $0.80 = 7,500 shares.
So, an investor would need to own approximately $1,509,225 worth of Alphabet, or 7,500 shares to generate a monthly dividend income of $500.
Assuming a more conservative goal of $100 monthly ($1,200 annually), we do the same calculation: $1,200 / $0.80 = 1,500 shares, or $301,845 to generate a monthly dividend income of $100.
Note that dividend yield can change on a rolling basis, as the dividend payment and stock price both fluctuate over time.
The dividend yield is calculated by dividing the annual dividend payment by the current stock price. As the stock price changes, the dividend yield will also change.
For example, if a stock pays an annual dividend of $2 and its current price is $50, its dividend yield would be 4%. However, if the stock price increases to $60, the dividend yield would decrease to 3.33% ($2/$60).
Conversely, if the stock price decreases to $40, the dividend yield would increase to 5% ($2/$40).
Further, the dividend payment itself can also change over time, which can also impact the dividend yield. If a company increases its dividend payment, the dividend yield will increase even if the stock price remains the same. Similarly, if a company decreases its dividend payment, the dividend yield will decrease.
GOOG Price Action: Shares of Alphabet fell by 1.4% to close at $201.23 on Monday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43432950/jim-cramer-appfolio-is-a-cheap-stock-dont-sell-this-tech-stock">Jim Cramer Says AppFolio Is A &#8216;Good One,&#8217; But Summit Therapeutics? &#8216;Can&#8217;t Go There&#8217;</a></li>
</ul>
Photo: Shutterstock

Long Ideas

How To Earn $500 A Month From Alphabet Stock Ahead Of Q4 Earnings (CORRECTED)

TD Cowen analyst Lance Vitanza maintains DraftKings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>) with a Buy and lowers the price target from $55 to $51.

DKNG

TD Cowen Maintains Buy on DraftKings, Lowers Price Target to $51

TD Cowen analyst Lance Vitanza maintains Caesars Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CZR#NASDAQ">CZR</a>) with a Buy and lowers the price target from $50 to $48.

TD Cowen Maintains Buy on Caesars Entertainment, Lowers Price Target to $48

Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) reported better-than-expected second-quarter financial <a href="https://www.benzinga.com/quote/CAH/earnings">results on Thursday</a>.
Cardinal Health posted adjusted earnings of $1.93 per share, beating market estimates of $1.76 per share. The company posted sales of $55.3 billion, topping expectations of $54.915 billion.
&#8220;We delivered strong second quarter financial results while taking significant strategic and operational actions to position us for future growth,&#8221; said Jason Hollar, CEO of Cardinal Health. &#8220;Led by robust demand across our Pharmaceutical and Specialty Solutions segment, we are again pleased to raise our fiscal 2025 enterprise guidance.&#8221;
Cardinal Health raised its FY25 non-GAAP earnings guidance from $7.75-$7.90 per share to $7.85-$8.00 per share.
Cardinal Health shares gained 1.3% to trade at $126.92 on Tuesday.
These analysts made changes to their price targets on Cardinal Health following earnings announcement.
<ul>
<li>Wells Fargo analyst Stephen Baxter maintained Cardinal Health with an Equal-Weight and raised the price target from $135 to $136.</li>
<li>JP Morgan analyst Lisa Gill maintained Cardinal Health with a Neutral and raised the price target from $142 to $145.</li>
</ul>
Considering buying CAH stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="575" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04133226/image-2-5-1024x575.png" alt="" class="wp-image-765459" style="width:609px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04133226/image-2-5-1024x575.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04133226/image-2-5-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04133226/image-2-5-768x431.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04133226/image-2-5.png 1116w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43463896/mcdonalds-to-290-here-are-10-top-analyst-forecasts-for-tuesday">McDonald&#8217;s To $290? Here Are 10 Top Analyst Forecasts For Tuesday</a></li>
</ul>

Cardinal Health Analysts Raise Their Forecasts Following Upbeat Earnings

TD Cowen analyst Lance Vitanza downgrades NAPCO Security Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSSC#NASDAQ">NSSC</a>) from Buy to Hold and lowers the price target from $46 to $27.

Downgrades

NSSC

TD Cowen Downgrades NAPCO Security Techs to Hold, Lowers Price Target to $27

On Tuesday, Cumberland Pharmaceuticals Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPIX#NASDAQ">CPIX</a>) released topline results from its <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/n43459112/cumberland-pharmaceuticals-announces-breakthrough-results-from-the-phase-2-fight-dmd-trial-in-duch" rel="noreferrer noopener">Phase 2 FIGHT DMD trial</a>.
The study evaluated ifetroban, a novel oral therapy for Duchenne muscular dystrophy (DMD) heart disease – the leading cause of <a target="_blank" href="https://www.benzinga.com/quote/CPIX" rel="noreferrer noopener">death in DMD patients</a>.
DMD is a rare and incurable pediatric disease caused by mutations in the gene encoding dystrophin, a protein critical for muscle function, including the heart.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42419338/why-is-cumberland-pharmaceuticals-stock-trading-over-100-on-tuesday" rel="noreferrer noopener">Why Is Cumberland Pharmaceuticals Stock Trading Over 100% on Tuesday?</a>
Patients with DMD slowly lose muscle function, resulting in the inability to walk, difficulty breathing, and heart failure.
The trial enrolled 41 patients who received either low-dose ifetroban (150 mg per day), high-dose ifetroban (300 mg per day), or placebo.
The study&#8217;s primary endpoint was an improvement in the heart&#8217;s left ventricular ejection fractions (LVEF), a key indicator of how well the heart is pumping blood.&nbsp;
Key findings include:
<ul>
<li>High-dose ifetroban treatment resulted in an overall 3.3% improvement in LVEF.</li>
<li>The high-dose ifetroban group showed an increase in 1.8% in LVEF, while the study placebo group showed an expected decline in LVEF of 1.5%</li>
<li>The difference was even more pronounced when compared with propensity-matched natural history controls, with the high-dose treatment providing a significant 5.4% overall improvement in LVEF, while the control patients experienced a 3.6% decline.</li>
<li>Both doses of ifetroban were well-tolerated, with no serious drug-related events.</li>
</ul>
Ifetroban has received both&nbsp;Orphan Drug Designation&nbsp;and&nbsp;Rare Pediatric Disease Designation&nbsp;from the FDA. If approved, ifetroban would be the first therapy specifically indicated for DMD-related heart disease.
Price Action: CPIX stock is up 23.01% at $2.62 at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43459558/novo-nordisk-faces-investor-concerns-over-hybrid-cagrisema-trial-results-for-weight-loss" target="_blank" rel="noreferrer noopener">Novo Nordisk Faces Investor Concerns Over Hybrid CagriSema Trial Results For Weight Loss</a></li>
</ul>

Biotech

Health Care

Movers

CPIX

Cumberland Pharmaceuticals' Duchenne Candidate Shows Improved Heart Function In Patients With Associated Heart Disease

HSBC analyst Edoardo Spina downgrades Autoliv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALV#NYSE">ALV</a>) from Buy to Hold and lowers the price target from $109 to $100.

HSBC Downgrades Autoliv to Hold, Lowers Price Target to $100

Deep-pocketed investors have adopted a bearish approach towards Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in AAPL usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 80 extraordinary options activities for Apple. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 37% leaning bullish and 43% bearish. Among these notable options, 18 are puts, totaling $2,635,916, and 62 are calls, amounting to $3,937,782.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $100.0 to $285.0 for Apple during the past quarter. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Apple's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Apple's whale trades within a strike price range from $100.0 to $285.0 in the last 30 days. 
<h3>Apple 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738693833_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>AAPL</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/14/25</td>
<td>$3.15</td>
<td>$3.05</td>
<td>$3.05</td>
<td>$227.50</td>
<td>$1.8M</td>
<td>2.0K</td>
<td>6.7K</td>
</tr>
<tr>
<td>AAPL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$135.5</td>
<td>$134.7</td>
<td>$135.13</td>
<td>$100.00</td>
<td>$270.2K</td>
<td>1.1K</td>
<td>30</td>
</tr>
<tr>
<td>AAPL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$13.1</td>
<td>$12.9</td>
<td>$13.1</td>
<td>$260.00</td>
<td>$262.0K</td>
<td>14.4K</td>
<td>221</td>
</tr>
<tr>
<td>AAPL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$8.75</td>
<td>$8.6</td>
<td>$8.73</td>
<td>$275.00</td>
<td>$240.9K</td>
<td>6.6K</td>
<td>281</td>
</tr>
<tr>
<td>AAPL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$134.95</td>
<td>$134.25</td>
<td>$134.67</td>
<td>$100.00</td>
<td>$188.5K</td>
<td>1.1K</td>
<td>74</td>
</tr>
</tbody>
</table>

<h3>About Apple</h3>
Apple is among the largest companies in the world, with a broad portfolio of hardware and software products targeted at consumers and businesses. Apple's iPhone makes up a majority of the firm sales, and Apple's other products like Mac, iPad, and Watch are designed around the iPhone as the focal point of an expansive software ecosystem. Apple has progressively worked to add new applications, like streaming video, subscription bundles, and augmented reality. The firm designs its own software and semiconductors while working with subcontractors like Foxconn and TSMC to build its products and chips. Slightly less than half of Apple's sales come directly through its flagship stores, with a majority of sales coming indirectly through partnerships and distribution.
After a thorough review of the options trading surrounding Apple, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Current Position of Apple</h3>
<ul>
<li>Trading volume stands at 24,595,000, with AAPL's price up by 1.67%, positioned at $231.82.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 86 days.</li>
</ul>
<h3>What The Experts Say On Apple</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $264.8.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Morgan Stanley continues to hold a Overweight rating for Apple, targeting a price of $275. 
&#x2A; An analyst from Loop Capital has revised its rating downward to Hold, adjusting the price target to $230. 
&#x2A; In a cautious move, an analyst from Needham downgraded its rating to Buy, setting a price target of $260. 
&#x2A; Consistent in their evaluation, an analyst from Goldman Sachs keeps a Buy rating on Apple with a target price of $294. 
&#x2A; Maintaining their stance, an analyst from B of A Securities continues to hold a Buy rating for Apple, targeting a price of $265. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Apple options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Behind the Scenes of Apple's Latest Options Trends

Evaxion Biotech (EVAX) has received notice from the Nasdaq Stock Market that it has been granted a 180-day extension to comply with Nasdaq's minimu...

Evaxion Biotech granted 180-day compliance extension by Nasdaq

Evaxion granted 180-day compliance extension by Nasdaq

An announcement from Evaxion Biotech ( ($EVAX) ) is now available. On January 28, 2025, Evaxion Biotech announced it received a 180-day extension f...

Evaxion Secures Nasdaq Compliance Extension Amid Equity Restoration

Evaxion Biotech ( ($EVAX) ) has provided an update. On January 30, 2025, Evaxion Biotech announced the pricing of a $10.8 million public offering o...

Evaxion Biotech Announces $10.8 Million Public Offering to Advance Vaccine Development

Evaxion Biotech stock slides after pricing $10.8M securities offering

Evaxion Biotech ( ($EVAX) ) has shared an announcement. On January 31, 2025, Evaxion Biotech A/S announced the successful closing of a $10.8 millio...

Evaxion Biotech Closes $10.8 Million Public Offering to Boost Vaccine Development

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Evaxion Biotech (EVAX – Research Report) and Protali...

Analysts Offer Insights on Healthcare Companies: Evaxion Biotech (EVAX) and Protalix (PLX)

Swayampakula Ramakanth, an analyst from H.C. Wainwright, maintained the Buy rating on Evaxion Biotech (EVAX – Research Report). The associated pric...

Evaxion Biotech's Financial Maneuvers and Collaborations Strengthen Buy Rating Despite Risks

Lake Street lowered the firm's price target on Evaxion Biotech (EVAX) to $6 from $35 and keeps a Buy rating on the shares after the company closed ...

Evaxion Biotech price target lowered to $6 from $35 at Lake Street

In a report released today, Thomas Flaten from Lake Street maintained a Buy rating on Evaxion Biotech (EVAX – Research Report), with a price target...

Comments

Evaxion Biotech

ニュース

最新ニュース Evaxion Biotech (NASDAQ:EVAX) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル